Result of Oncology Ventures Drug Response Prediction for TKI drug from Big Pharma available in third week of January 2018
Hoersholm, Denmark, December 14th, 2017 – Oncology Venture AB (OV:ST) announces updated timeline for receiving results of the patient response prediction (DRP) for an undisclosed small molecule, kinase inhibitor (TKI) from Novartis Pharma AG (Basel, Switzerland) which has been in phase 3 in renal cancer patients. The initial report performed by Novartis is expected to be available and communicated in third week of January. The timeline for this publication has previously been communicated as 6-8 weeks from the 23 October 2017. The analysis of the tumor tissue is performed by a third party on